drugset
drugset / Trial / NCT06438250

68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

NCT06438250 ↗

Phase 0 Recruiting 5 enrolled First Affiliated Hospital of Fujian Medical University
NaSingle-groupOpen-labelDiagnostic

Summary

68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.

Timeline

Start
2024-03-01
Primary completion
2025-05-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-JH04 Diagnostic / imaging agent 148 mbq Intravenous
Subject 68Ga-JH04 Diagnostic / imaging agent 222 mbq Intravenous

Indications

cancer